Diffuse Intrinsic Pontine Glioma Clinical Trials

18 studies are recruiting for diffuse intrinsic pontine glioma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Targeted Pediatric High-Grade Glioma Therapy

   The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical …

   Stage

   Not phased

   Ages

   1 to 39

   Site

   Children's National Medical Center, Washington D.C., District of Columbia

   Locations

   22 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05839379 on ClinicalTrials.gov

2. Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

   The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authorities around the world for use alone …

   Stage

   Phase 1

   Ages

   Up to 26

   Site

   University of Alabama/Children's of Alabama, Birmingham, Alabama

   Locations

   14 in total

   Run by

   Milton S. Hershey Medical Center

   See if you can join NCT06465199 on ClinicalTrials.gov

3. Study of Olutasidenib and Temozolomide in HGG

   The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozol…

   Stage

   Phase 2

   Ages

   12 to 39

   Site

   University of Miami Hospital and Clinics, Miami, Florida

   Locations

   20 in total

   Run by

   Rigel Pharmaceuticals

   See if you can join NCT06161974 on ClinicalTrials.gov

4. PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

   This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a v…

   Stage

   Phase 2

   Ages

   3 to 39

   Site

   Children's Hospital Colorado, Aurora, Colorado

   Locations

   13 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05096481 on ClinicalTrials.gov

5. Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

   This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG). DIPG is a rare and aggressive brain tumor with limited treatment options. CAR T cell therapy uses a patient'…

   Stage

   Phase 2

   Ages

   1 to 26

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   6 in total

   Run by

   BrainChild Bio, Inc

   See if you can join NCT07680439 on ClinicalTrials.gov

6. C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

   In this study, there are two treatment groups called Cohort 1 and Cohort 2. Cohort 1 is for patients with diffuse midline glioma, diffuse intrinsic pontine glioma, medulloblastoma, or another rare high-grade glioma that expresses GD2. Cohort 2 is for patients with a type of cancer called progressiv…

   Stage

   Phase 1

   Ages

   1 to 25

   Site

   Texas Children's Hospital, Houston, Texas

   Run by

   Baylor College of Medicine

   See if you can join NCT04099797 on ClinicalTrials.gov

7. Atovaquone Combined With Radiation in Children With Malignant Brain Tumors

   The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade glioma/diffuse midline glioma/diffuse intrinsic pontine glioma (pHGG/DMG…

   Stage

   Phase 1

   Ages

   2 to 25

   Site

   Arthur M Blank Hospital, Atlanta, Georgia

   Locations

   2 in total

   Run by

   Emory University

   See if you can join NCT06624371 on ClinicalTrials.gov

8. PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy

   A Phase I open-label, multicenter study, to evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in combination with adoptive cell therapy (Total tumor mRNA-pulsed autologous Dend…

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   University of Florida, Gainesville, Florida

   Locations

   3 in total

   Run by

   University of Florida

   See if you can join NCT04837547 on ClinicalTrials.gov

9. Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

   The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with chemotherapy or after radiation therapy.

   Stage

   EARLY_Phase 1

   Ages

   1 to 21

   Site

   Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

   Locations

   18 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT06333899 on ClinicalTrials.gov

10. Combination Therapy for the Treatment of Diffuse Midline Gliomas

    This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for participants with DMGs, and there are few treatment opt…

    Stage

    Phase 2

    Ages

    2 to 39

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    32 in total

    Run by

    University of California, San Francisco

    See if you can join NCT05009992 on ClinicalTrials.gov

11. Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

    The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target or 2) ribociclib …

    Stage

    Phase 2

    Ages

    1 to 39

    Site

    Children's National Medical Center, Washington D.C., District of Columbia

    Locations

    20 in total

    Run by

    Nationwide Children's Hospital

    See if you can join NCT05843253 on ClinicalTrials.gov

12. Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

    This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt. CAR T cells are delivered via an indwelling catheter into the tumor resection cav…

    Stage

    Phase 1

    Ages

    1 to 26

    Site

    Seattle Children's Hospital, Seattle, Washington

    Run by

    Seattle Children's Hospital

    See if you can join NCT04185038 on ClinicalTrials.gov

13. A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

    This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given. The study will also evaluate the safety of larotrectinib when given with …

    Stage

    EARLY_Phase 1

    Ages

    Up to 21

    Site

    Children's Hospital Colorado, Aurora, Colorado

    Locations

    21 in total

    Run by

    Nationwide Children's Hospital

    See if you can join NCT04655404 on ClinicalTrials.gov

14. rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

    This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein containing 16 peptides reflecting neo-epitopes found in the majority …

    Stage

    Phase 1

    Ages

    1 to 18

    Site

    Children's Health Orange County (CHOC), Orange, California

    Locations

    3 in total

    Run by

    Ann & Robert H Lurie Children's Hospital of Chicago

    See if you can join NCT04943848 on ClinicalTrials.gov

15. FUS Etoposide for DMG

    The blood brain barrier (BBB) prevents some drugs from successfully reaching the target tumor. Focused Ultrasound (FUS) using microbubbles and neuro-navigator controlled sonication is a non-invasive method of temporarily opening up the blood brain barrier to allow a greater concentration of the dru…

    Stage

    Phase 1

    Ages

    4 to 21

    Site

    Columbia University Irving Medical Center, New York, New York

    Run by

    Columbia University

    See if you can join NCT05762419 on ClinicalTrials.gov

16. Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

    This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients < 22 years of age.

    Stage

    Phase 1

    Ages

    1 to 21

    Site

    Jackson Memorial Hospital, Miami, Florida

    Run by

    University of Miami

    See if you can join NCT05956821 on ClinicalTrials.gov

17. International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository

    Doctors and other medical scientists want learn about the biology of DIPG/DMG and to develop better ways to diagnose and treat patients with DIPG/DMG. To do this, they need more information about the characteristics of DIPG/DMG tumors. Therefore, they want to establish a central location for clinic…

    Stage

    Not phased

    Ages

    Any age

    Site

    Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

    Run by

    Children's Hospital Medical Center, Cincinnati

    See if you can join NCT03101813 on ClinicalTrials.gov

18. Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma

    The purpose of this study is to prospectively collect specimens from pediatric patients with diffuse intrinsic pontine glioma or brainstem glioma, either during therapy or at autopsy, in order to characterize the molecular abnormalities of this tumor.

    Stage

    Not phased

    Ages

    Up to 21

    Site

    Children's National Medical Center, Washington D.C., District of Columbia

    Run by

    Children's National Research Institute

    See if you can join NCT01106794 on ClinicalTrials.gov